Geroprotectors as a therapeutic strategy for COPD – where are we now?

Geroprotectors as a therapeutic strategy for COPD – where are we now?

Joanna Miłkowska-Dymanowska,1,2 Adam J Białas,1,2 Joanna Makowska,2,3 Aleksandra Wardzynska,2,4 Paweł Górski,1,2 Wojciech J Piotrowski1,2 1Department of Pneumology and Allergy, 1st Chair of Internal Medicine, 2Healthy Aging Research Centre, 3Department of Rheumatology, 4Department of Imm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Miłkowska-Dymanowska J, Białas AJ, Makowska J, Wardzynska A, Górski P, Piotrowski WJ
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
COPD
metformin
melatonin
statins
vitamin D
testosterone
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/18d3b333edd144d7865d3aff83864e3e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:18d3b333edd144d7865d3aff83864e3e
record_format dspace
spelling oai:doaj.org-article:18d3b333edd144d7865d3aff83864e3e2021-12-02T02:47:41ZGeroprotectors as a therapeutic strategy for COPD – where are we now?1178-1998https://doaj.org/article/18d3b333edd144d7865d3aff83864e3e2017-10-01T00:00:00Zhttps://www.dovepress.com/geroprotectors-as-a-therapeutic-strategy-for-copd-where-are-we-now-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Joanna Miłkowska-Dymanowska,1,2 Adam J Białas,1,2 Joanna Makowska,2,3 Aleksandra Wardzynska,2,4 Paweł Górski,1,2 Wojciech J Piotrowski1,2 1Department of Pneumology and Allergy, 1st Chair of Internal Medicine, 2Healthy Aging Research Centre, 3Department of Rheumatology, 4Department of Immunology, Rheumatology, and Allergy, Medical University of Lodz, Lodz, Poland Abstract: Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality. There are still many gaps in knowledge about the cellular, molecular, and genetic mechanisms contributing to pathobiology of this disease. However, increasing evidence suggests that accelerated aging, chronic systemic inflammation, and oxidative stress play major roles in pathogenesis in COPD, thus opening new opportunities in therapy. Therefore, the aim of our review was to describe and discuss some of the most widely used therapeutics that affect the root cause of aging and oxidative stress (metformin, melatonin, sirolimus, statins, vitamin D, and testosterone) in context of COPD therapy. Keywords: COPD, metformin, melatonin, statins, vitamin D, testosteroneMiłkowska-Dymanowska JBiałas AJMakowska JWardzynska AGórski PPiotrowski WJDove Medical PressarticleCOPDmetforminmelatoninstatinsvitamin DtestosteroneGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 12, Pp 1811-1817 (2017)
institution DOAJ
collection DOAJ
language EN
topic COPD
metformin
melatonin
statins
vitamin D
testosterone
Geriatrics
RC952-954.6
spellingShingle COPD
metformin
melatonin
statins
vitamin D
testosterone
Geriatrics
RC952-954.6
Miłkowska-Dymanowska J
Białas AJ
Makowska J
Wardzynska A
Górski P
Piotrowski WJ
Geroprotectors as a therapeutic strategy for COPD – where are we now?
description Joanna Miłkowska-Dymanowska,1,2 Adam J Białas,1,2 Joanna Makowska,2,3 Aleksandra Wardzynska,2,4 Paweł Górski,1,2 Wojciech J Piotrowski1,2 1Department of Pneumology and Allergy, 1st Chair of Internal Medicine, 2Healthy Aging Research Centre, 3Department of Rheumatology, 4Department of Immunology, Rheumatology, and Allergy, Medical University of Lodz, Lodz, Poland Abstract: Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality. There are still many gaps in knowledge about the cellular, molecular, and genetic mechanisms contributing to pathobiology of this disease. However, increasing evidence suggests that accelerated aging, chronic systemic inflammation, and oxidative stress play major roles in pathogenesis in COPD, thus opening new opportunities in therapy. Therefore, the aim of our review was to describe and discuss some of the most widely used therapeutics that affect the root cause of aging and oxidative stress (metformin, melatonin, sirolimus, statins, vitamin D, and testosterone) in context of COPD therapy. Keywords: COPD, metformin, melatonin, statins, vitamin D, testosterone
format article
author Miłkowska-Dymanowska J
Białas AJ
Makowska J
Wardzynska A
Górski P
Piotrowski WJ
author_facet Miłkowska-Dymanowska J
Białas AJ
Makowska J
Wardzynska A
Górski P
Piotrowski WJ
author_sort Miłkowska-Dymanowska J
title Geroprotectors as a therapeutic strategy for COPD – where are we now?
title_short Geroprotectors as a therapeutic strategy for COPD – where are we now?
title_full Geroprotectors as a therapeutic strategy for COPD – where are we now?
title_fullStr Geroprotectors as a therapeutic strategy for COPD – where are we now?
title_full_unstemmed Geroprotectors as a therapeutic strategy for COPD – where are we now?
title_sort geroprotectors as a therapeutic strategy for copd – where are we now?
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/18d3b333edd144d7865d3aff83864e3e
work_keys_str_mv AT miłkowskadymanowskaj geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
AT białasaj geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
AT makowskaj geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
AT wardzynskaa geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
AT gorskip geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
AT piotrowskiwj geroprotectorsasatherapeuticstrategyforcopdndashnbspwherearewenow
_version_ 1718402146563522560

Ejemplares similares